Alemtuzumab? Alemtuzimab is a common misspelling of alemtuzumab.
Alemtuzumab (Campath®) is a drug used to treat a specific kind of chronic lymphocytic leukemia. It is available as an injection and is administered by a healthcare provider. In a clinical study, alemtuzumab was shown to extend the period of time leukemia does not progress, more so than chlorambucil (Leukeran®), another leukemia medicine. In the study, people who received alemtuzumab went about 14.6 months without their condition getting worse, compared with 11.7 months in people taking chlorambucil.
(Click Alemtuzumab to learn more about this medicine, including how it works, possible side effects, dosing guidelines, and more. You can also click any of the links in the box to the right for specific information.)
HealthSavvy Sign In
|